Shift Labs
Winter 2015AcquiredMakers of simple, affordable medical devices. Our award-winning…
Pressure-test this opportunity
Explore the risks and possibilities with a prompt for ChatGPT, Claude, or your agent.
Makers of simple, affordable medical devices. Our award-winning…
Explore the risks and possibilities with a prompt for ChatGPT, Claude, or your agent.
Shift Labs was a Seattle-based medical device startup founded in 2012 by Beth Kolko and Koji Intlekofer. The company's flagship product, DripAssist, was a $225 IV drip rate monitor designed to bring basic infusion safety to healthcare settings where $5,000–$15,000 infusion pumps were impractical or unavailable. Shift Labs participated in Y Combinator's Winter 2015 batch and spent the following seven years building distribution across home care, military, and global health channels, earning FDA clearance, CE marking, and a string of industry awards along the way.
The company's core thesis — that incumbents deliberately avoided low-margin devices, leaving a real clinical gap — was correct. But being correct about the gap did not resolve the underlying economics: selling $225 devices at scale requires either very high volume or a radically lean distribution model, and Shift Labs achieved neither before its capital ran thin.
Shift Labs was ultimately acquired, with the acquirer undisclosed. The July 2020 licensing deal granting Hometa exclusive Americas distribution rights signaled that independent scaling had stalled. Founder Beth Kolko transitioned to venture capital roles beginning in 2019, and her biography references approximately ten years as CEO — consistent with a 2012–2022 operational window. The product continues to exist; the independent company did not.
Image 1 / 2
Beth Kolko came to medical device entrepreneurship through an unusual path. A professor of Human Centered Design and Engineering at the University of Washington,[1] her academic work focused on technology in low-resource settings — the kind of environments where clinical infrastructure is sparse and the gap between what patients need and what they can access is widest. That research lens shaped the founding insight behind Shift Labs: the medical device industry was not failing to serve low-resource settings by accident. It was doing so by design.
Kolko articulated this directly in a 2015 TechCrunch interview, recounting a conversation with a medical device executive: "I once had a VP of a medical device company who took me aside and said, 'We could make simpler and cheaper devices, but then our revenue wouldn't support our sales force.'"[2] The incumbent business model — high-margin devices sold through expensive direct sales forces — structurally excluded the lower end of the market. Kolko saw that as an opportunity.
Shift Labs was founded in 2012 in Seattle.[3] The original co-founder departed in 2013 due to family issues,[4] a meaningful early disruption — though no public record describes what that person contributed or what was lost in the transition. Koji Intlekofer subsequently joined as co-founder and CTO.[5] No public record describes how Kolko and Intlekofer met or what Intlekofer's background was prior to Shift Labs.
The company's early framing was deliberately ambitious: Shift Labs would be "the Nest of medical devices."[6] The analogy was to Nest's achievement of bringing consumer-grade simplicity and design quality to a commodity hardware category — applied here to clinical hardware. It was a compelling positioning, though as later events would show, the analogy had limits. Nest sold premium hardware at premium margins into a mass consumer market. Shift Labs would be selling low-margin clinical hardware into fragmented, grant-dependent channels.
In Winter 2015, Kolko and Intlekofer relocated from Seattle to Silicon Valley to join Y Combinator's W15 batch, spending three months refining their business plan and sales pitch.[7] The YC experience left a lasting mark on the team's operating philosophy. As Intlekofer later described it: "YC was instrumental in helping us think about building a medical device company like a fast-moving startup, and not make excuses for moving slowly just because the medical device industry has traditionally moved slowly."[8]
That philosophy — move fast, sidestep incumbents, find the underserved channel — defined Shift Labs' strategy for the next seven years.
Shift Labs built DripAssist, a device that solved a specific and underappreciated clinical problem: how do you safely monitor an IV drip in a setting where a powered infusion pump is unavailable, unaffordable, or impractical?
The standard answer in well-resourced hospitals is an electronic infusion pump — a device that actively controls flow rate, detects occlusions, and alarms on deviation. These pumps cost between $5,000 and $15,000 per unit,[30] require training, maintenance, and power infrastructure, and are effectively absent from home care settings, field medicine, and most of the developing world. In those settings, gravity-based infusions — where a bag of fluid drains through a tube by gravity alone — remain the norm. The problem is that gravity infusions have no built-in rate control or alarm. A nurse must manually count drip drops and adjust a clamp. If the rate drifts, no one knows until a patient is harmed.
DripAssist addressed this gap with deliberate simplicity. The device clips onto any standard IV drip chamber — no proprietary tubing required — and uses an optical sensor to count individual drops as they fall. It calculates the drip rate in real time, displays it on a small screen, and sounds an alarm if the rate deviates above or below a clinician-set threshold.[31] The entire device runs for 360 hours on a single AA battery.[32] Setup time dropped from roughly ten minutes of manual calculation to under one minute.[33]
The retail price was $225 — a deliberate 10–66x reduction versus standard pumps.[34] Shift Labs claimed the device could enable 70% of infusions currently performed with expensive pumps to shift to gravity-based delivery with no impact on patient safety, and could reduce the cost of monitoring gravity infusions by up to 50%.[35] These claims have not been independently validated in peer-reviewed literature available in public sources.
The regulatory path was sequenced carefully. Shift Labs sold DripAssist internationally and in veterinary markets first, generating early revenue and real-world data while pursuing FDA clearance.[36] FDA 510(k) clearance (K150687) was granted in November 2015.[37] The device was also CE-marked and ISO 13485 certified, enabling European and broader international sales.[38] A second product, DripAssist Plus, received its own FDA 510(k) clearance in May 2018 (K172242),[39] though public sources do not describe how it differed from the original.
Beyond DripAssist, Shift Labs had devices in oxygen and temperature control in internal R&D as of September 2015,[40] and also developed an amniotome with a protected sharp.[41] No evidence suggests these reached commercial launch. The company filed 7 patents,[42] indicating meaningful investment in protecting its core IP even as the product line remained narrow.
What distinguished DripAssist from alternatives was not technological sophistication but deliberate constraint: no proprietary consumables, no power dependency, no training burden, no service contract. In the markets Shift Labs targeted, those constraints were features.
Shift Labs explicitly sidestepped the primary US hospital market. As CTO Koji Intlekofer stated in 2015: "The traditional United States hospital industry is a very complicated environment, and for now, we're just sidestepping it to focus on making things for this much wider opportunity."[43] The reasoning was straightforward: nearly every US hospital bed already has an infusion pump, eliminating DripAssist's value proposition in acute inpatient care.
Instead, Shift Labs pursued four distinct customer segments. Home healthcare providers — where patients receive IV antibiotics, chemotherapy, or nutrition at home without access to hospital-grade equipment — represented the most commercially developed US channel, anchored by the Option Care national partnership in 2018.[44] Military and field medicine users, where portability and battery life matter more than connectivity, were validated by the Air Force SBIR contract and subsequent investment.[45] Global health and humanitarian organizations — including deployments in Liberia and Sierra Leone during the Ebola response[46] — represented the segment most aligned with Kolko's academic background. Outpatient infusion clinics rounded out the domestic opportunity.
The global IV infusion therapy market is large — typically estimated in the tens of billions of dollars — but Shift Labs was not competing for that market. It was competing for the subset of infusion settings where pumps are absent or impractical: home care, field medicine, and low-resource international settings. This is a structurally fragmented market with no single dominant buyer, which creates distribution complexity that a small team struggles to navigate efficiently.
The home infusion market in the US was growing through the 2010s, driven by cost pressures pushing care out of hospitals. The Option Care partnership — covering national home infusion services — was the clearest signal that this channel had real scale potential. But home infusion providers are themselves cost-sensitive buyers, which reinforces the margin pressure on a $225 device.
Shift Labs' competitive position is best understood along two axes: price versus safety assurance, and distribution reach versus product simplicity.
On the price-safety axis, DripAssist occupied a deliberate middle ground. Below it sat manual drip counting — free, but error-prone and labor-intensive. Above it sat electronic infusion pumps at $5,000–$15,000, with full flow control but requiring power, training, and maintenance infrastructure. DripAssist offered monitoring and alarming without active flow control — a meaningful safety improvement over manual counting at a fraction of pump cost.
The structural competitive risk was not from direct competitors building similar devices — no major incumbent had incentive to cannibalize its own pump business with a $225 monitor — but from the distribution channels themselves. Home infusion providers like Option Care could, in principle, standardize on pumps for all patients rather than adopting a hybrid model. The fact that Option Care ran a 16-city pilot before committing to a national rollout suggests the value proposition was real but required validation before buyers would commit.
The more durable competitive threat was platform dependency. Shift Labs' international and global health traction depended heavily on grant funding from USAID and similar organizations. When grant priorities shift — as they did after the acute Ebola response wound down — procurement pipelines dry up regardless of product quality. This is not a competitive dynamic in the traditional sense, but it functions like one: the "competitor" is the next grant cycle's priority.
Shift Labs sold DripAssist as a capital purchase at $225 per unit, with no disclosed recurring revenue model (no consumables, no service contracts, no software subscription). This is a structurally thin model for a regulated medical device company: revenue is one-time per unit, and the device's long battery life and durability reduce replacement frequency.
The company never disclosed revenue figures. The absence of any revenue disclosure across eight years of press coverage — even in the context of fundraising announcements — is itself a signal that commercial scale remained modest.
Inferring from available data: with approximately $2–4M in total capital raised across equity and grants over ten years,[47][48] and a team of approximately six employees as of 2015,[49] annual burn was likely in the $500K–$1M range (inference, not confirmed). At $225 per unit, Shift Labs would need to sell thousands of units annually just to approach breakeven — and that assumes gross margins sufficient to cover regulatory maintenance, quality systems, and sales costs, none of which are disclosed.
The grant-heavy funding mix — USAID ($300K), Saving Lives at Birth, Air Force SBIR, HHS ($1.84M) — is consistent with a company that found commercial revenue insufficient to fund operations independently and relied on mission-aligned public funding to bridge gaps. The $1.84M HHS grant in September 2022, the latest known funding event, suggests the company was still grant-dependent a decade into its existence.[50]
Shift Labs achieved genuine multi-channel deployment over its lifetime, though volume remained modest relative to the addressable market.
By July 2020, DripAssist had been deployed in over 200 healthcare settings across the US — spanning military field settings, outpatient infusion clinics, and home care — and in more than 15 countries internationally.[51][52] The company reported selling "thousands of devices" and building partnerships with the US military, US home care services, and major global health organizations.[53]
The most commercially significant milestone was the Option Care national partnership in July 2018, following a 16-city pilot.[54] Option Care is one of the largest home infusion providers in the US, and a national rollout represented the clearest path to volume. A parallel partnership with New England Life Care followed in October 2018.[55]
Institutional validation was strong: WHO and UNICEF interest in 2015 (though no evidence of conversion to procurement contracts),[56] Ebola response deployments in Liberia and Sierra Leone,[57] and COVID-19 and disaster relief use. Award recognition included Popular Science's Best Healthcare Innovation 2016,[58] the IDSA IDEA Silver Medal 2015,[59] and the MedTech Global Health Innovator Award 2017.[60]
The honest read of these numbers: "200+ settings" and "thousands of devices" over eight years, across a company with FDA clearance, a national home care partnership, and military adoption, suggests that volume plateaued well below what would be needed to sustain independent operations. The breadth of deployment contexts — military, global health, home care, disaster relief — reflects a team chasing every available channel rather than dominating any single one.
The central failure of Shift Labs was not a product failure, a regulatory failure, or a market timing failure. It was a structural mismatch between the economics of the product and the capital requirements of the business.
Developing, clearing, and maintaining a regulated medical device is expensive regardless of the device's selling price. FDA 510(k) clearance, quality management systems (ISO 13485), CE marking, post-market surveillance, and ongoing regulatory compliance consume capital that scales with the number of products and markets, not with the device's price point. A Hacker News commenter familiar with the space noted in September 2015 that the 510(k) process alone could consume approximately $1M for a lean startup.[61] Shift Labs cleared two 510(k)s (November 2015 and May 2018), maintained CE marking and ISO 13485 certification, and pursued military and international regulatory pathways — all on a total capital base of approximately $2–4M across equity and grants over ten years.[62][63]
At $225 per unit with no recurring revenue, the math is unforgiving. Even at 50% gross margin — an optimistic assumption for a hardware device with manufacturing, quality, and warranty costs — each unit generates roughly $112 of gross profit. Covering $750K in annual operating expenses (a conservative estimate for a six-person regulated device company) would require selling approximately 6,700 units per year. "Thousands of devices" over eight years implies annual volumes well below that threshold.
The attempt to address this was the Hometa licensing deal in July 2020, which outsourced Americas manufacturing and distribution to a third party.[64] This reduced Shift Labs' operational burden but also reduced its revenue per unit — licensing royalties are structurally thinner than direct sales margins. The deal extended the product's life but did not resolve the underlying economics for the company.
Kolko's diagnosis of the incumbent market was accurate: large medical device companies deliberately avoid low-margin products because those products are incompatible with high-cost direct sales forces.[65] But this structural reality cuts both ways. The same logic that kept incumbents out of the market also made it difficult for Shift Labs to build a sustainable business there.
The home care channel — the most commercially developed US opportunity — is populated by cost-sensitive buyers who negotiate hard on device prices. The global health channel depends on grant funding cycles that are unpredictable and non-recurring. The military channel involves long procurement cycles and SBIR grants that fund development but do not guarantee volume purchasing. None of these channels offered the combination of volume, margin, and predictability that would support independent scale.
The Option Care national partnership in July 2018 was the clearest attempt to break through this constraint.[66] A national rollout with a major home infusion provider should have driven meaningful volume. That the company was still grant-dependent in September 2022 — four years after the Option Care announcement — suggests the partnership did not generate the commercial momentum the company needed.
Shift Labs' funding mix was heavily weighted toward non-dilutive grants: USAID ($300K, 2015), Saving Lives at Birth, Air Force AFWERX Phase I SBIR (2019), HHS ($1.84M, 2022).[67][68][69] Grant funding is valuable — it is non-dilutive and validates mission alignment — but it is also discontinuous, tied to specific use cases, and subject to government budget cycles.
The USAID Ebola grant in 2015 funded deployment in West Africa during an acute crisis. When the crisis ended, that funding stream ended. The Air Force SBIR funded a specific phase of military development. The HHS grant in 2022 funded a specific program. None of these created the recurring revenue base that would allow Shift Labs to plan and invest for growth.
The equity raise was correspondingly thin: approximately $1.6M in the 2015 seed round, with the total equity base estimated at $1.72M–$2.12M depending on the source.[70][71] For a regulated medical device company operating across multiple international markets with two cleared products, this is an extremely thin equity base. The company appears to have been perpetually capital-constrained, relying on the next grant to fund the next phase of operations.
The Nest analogy that defined Shift Labs' early positioning contained a hidden flaw. Nest succeeded by selling premium consumer hardware at high margins — the Nest thermostat retailed at $249 in 2011 and carried strong gross margins — into a mass consumer market with straightforward retail distribution. The company raised $80M in venture capital before being acquired by Google for $3.2B.
Shift Labs sold low-margin clinical hardware at $225 into fragmented, grant-dependent markets with complex regulatory and procurement requirements. The aesthetic and design philosophy translated. The business model did not. A more accurate analogy might have been a global health NGO with a product — an organization that creates real value and deploys real solutions, but is not structured to generate the returns that justify venture-scale capital.
This framing mismatch may have made it harder to raise the equity capital that would have been needed to scale distribution independently. Venture investors expecting Nest-like outcomes would have been disappointed by the structural realities of the market; impact investors and grant-makers were better aligned but provided non-recurring capital.
Identifying a market gap that incumbents deliberately avoid does not guarantee a sustainable business model. Shift Labs correctly diagnosed that large medical device companies avoided low-margin products because those products were incompatible with high-cost sales forces. But the same structural logic that kept incumbents out also made it difficult for Shift Labs to build a sustainable business: the channels available for a $225 device — home care, global health, military grants — were either cost-sensitive, grant-dependent, or both. The gap was real; the business model to fill it profitably was not.
Grant funding is a poor substitute for recurring commercial revenue in capital-intensive regulated industries. Shift Labs received grants from USAID, the Air Force, and HHS across its ten-year life, and was still grant-dependent in 2022. Each grant funded a specific phase or deployment context but did not create the recurring revenue base needed to sustain operations between grants. For a company with two FDA-cleared products, CE marking, and a national home care partnership, continued grant dependency a decade in signals that commercial revenue never reached self-sustaining levels.
Licensing distribution to a third party (Hometa, July 2020) can extend a product's life while signaling that the company has stopped believing in its own ability to scale. The Hometa deal gave Shift Labs' product access to Americas distribution without the cost of building it — a rational move given the capital constraints. But exclusive licensing of core distribution rights is structurally a wind-down move: it trades future upside for near-term operational relief. The deal preceded the acquisition by approximately two years, consistent with a company preparing for a transition rather than a growth phase.
The YC "move fast" philosophy is genuinely applicable to medical device development — but it does not change the capital math of regulated hardware. Intlekofer credited YC with helping Shift Labs think like a fast-moving startup rather than a traditional medical device company. The company did move fast: two FDA clearances, CE marking, and deployments across 15+ countries on minimal capital. But speed of execution did not resolve the fundamental tension between $225 device economics and the ongoing cost of regulatory compliance, quality systems, and distribution. Moving fast got the product to market; it did not make the market large enough to sustain the company.
A product that wins awards and serves real clinical needs can still fail to generate the commercial scale needed for independent operation. DripAssist won Popular Science's Best Healthcare Innovation, an IDSA IDEA Silver Medal, and the MedTech Global Health Innovator Award. It was deployed in Ebola response, COVID-19 relief, and military field settings. It received a national partnership with one of the US's largest home infusion providers. None of this translated into disclosed revenue, a growth equity round, or independent scale. Award recognition and institutional validation are signals of product quality, not commercial viability — and in medical devices, the gap between the two can be wide.